1. Generics Bulletin

Richter Takes Control Of German JVs To Wrap Up Teriparatide Biosimilar

Majority Owned CDMO With Three Sites Also Set To Move Into Richter’s Hands

 
• By Dean Rudge

Gedeon Richter is putting its hand back in its wallet following its recent investment in Formycon, opting to take control of a pair of joint ventures established with German firm Helm.

old abacus with bills of 500 euros close up

Hungarian player Gedeon Richter has struck agreements worth more than €100m ($109m) to buy out a couple of joint ventures from its long-term German partner Helm, including a JV (Richter-Helm BioLogics) that owns the Terrosa (teriparatide) biosimilar to Forteo/Forsteo, in a move it believes will “create a very strong biotechnology platform allowing even better service offerings in a cost-efficient way.”

Through a €71.8m purchase agreement, Richter is seeking to buy out Helm’s 50% stake in Richter-Helm BioTec GmbH & Co

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.